ZymoGenetics Will Ship Topical Hemostat Recothrom In Two Weeks
This article was originally published in The Pink Sheet Daily
Executive Summary
Company will price the recombinant, plasma-free thrombin at a 20 percent premium over competitor King's bovine-derived Thrombin JMI.
You may also be interested in...
ZymoGenetics Claims Competitor's Product Poses Serious Patient Safety Issue
As it tries to build market share for Recothrom, ZymoGenetics files Citizen's Petition asking FDA to remove its top competitor from the market.
ZymoGenetics Claims Competitor's Product Poses Serious Patient Safety Issue
As it tries to build market share for Recothrom, ZymoGenetics files Citizen's Petition asking FDA to remove its top competitor from the market.
Atacicept R&D Cost Gone, ZymoGenetics Makes Plans
Recothrom launch gains momentum as P&T committees meet, GPO deals are forged.